Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung ‐molGPA) in a Chinese cohort: A retrospective study of multiple institutions

In the era of precision medicine, as rising healthcare costs of cancers, it has become essential for the society as a whole to predict the prognosis of NSCLC with BM, whose survival outcomes present heterogeneity even though new treatments strategies such as SRS, molecular target and immune therapy are being developed. Based on the Lung ‐molGPA model, we generated an adjusted Lung‐molGPA model. It is aimed to verify the applicability of the adjusted Lung‐molGPA model for NSCLC with BM in a Chinese cohort that a retrospective study included 1903 patients at three hospitals in Southwest China. To our knowledge, this is the firs t multi‐center study about the applicability of adjusted Lung‐molGPA and DS‐GPA models in a Chinese cohort that the adjusted Lung‐molGPA model is better than the DS‐GPA model in predicting the prognosis of adenocarcinoma. AbstractBackgroundIn this era of precision medicine, prognostic heterogeneity is an important feature of patients with non ‐small cell lung cancer (NSCLC) with brain metastases (BM). This multi‐institutional study is aimed to verify the applicability of the adjusted Lung‐molGPA model for NSCLC with BM in a Chinese cohort.MethodsThis retrospective study included 1903 patients at three hospitals in Southwest China. The performance of the Lung ‐molGPA model was compared with that of the adjusted DS‐GPA model in terms of estimating the survival of NSCLC with BM.ResultsThe median OS of this patient cohort was 27.0 &...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research

Related Links:

More News: Adenocarcinoma | Brain | Brain Cancers | Cancer | Cancer & Oncology | China Health | Healthcare Costs | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Study